[Rhinofacial entomophthoromycosis. About two new cases in Mayotte].
Conidiobolus entomophthoromycosis is a rare mycosis due to an ubiquitary telluric fungus. Although the organism is found around the world, it is more concentrated in warm, wet climates. Cases have been described in West Africa, Australia, South America and India. Conidiobolus spp was also to be found in animal like horse. The transmission mode of Conidiobolus has not been established but probably occurs via inhalation of fungal spores covering the nasal mucous membrane or from a minor trauma such as an insect bite. The clinical syndromes include intranasal tumour, nasal obstruction, broadening of the nose bridge, paranasal sinuses, cheeks and upper lip. Diagnostic is made by demonstrating distinctive non-septate hyphea with surrounding eosinophilic sleeve (Splendore-Hoeppli phenomenom) in tissue sections. We report here two cases contracted in Comoro Islands. The first one was a 26 year-old man treated by amphotericin B during six weeks and then by itraconazole, with a clear improvement. The second one was a 37 year-old woman. She has been treated by amphotericin B, subsequently by imidazoles. There was a clear benefit on life duration, but the results for aesthetic aspect are not satisfactory. In the discussion, we review treatment efficacy and failure; in fact, surgery which includes removal of infected tissue and reconstructive procedures, is seldom curative. Several combinations of drugs have been used with different degrees of success. Nevertheless imidazoles remain more efficient than amphotericin B.
Receveur
M C
MC
Service de médecine interne et tropicale, Hôpital St-André, Centre hospitalier universitaire de Bordeaux, 1 rue Jean-Burguet, 33000 Bordeaux.
Roussin
C
C
Mienniel
B
B
Gasnier
O
O
Rivière
J P
JP
Malvy
D
D
Lortholary
O
O
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D020092:Conidiobolus / Q000302:isolation & purification*; D005145:Face / Q000382:microbiology*; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008297:Male; D009668:Nose Diseases / Q000382:microbiology*; D018461:Soft Tissue Infections / Q000382:microbiology*; D016896:Treatment Outcome; D020096:Zygomycosis / Q000175:diagnosis*
D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B; D015725:Fluconazole